1. Home
  2. CYRX vs ADCT Comparison

CYRX vs ADCT Comparison

Compare CYRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYRX

CryoPort Inc.

HOLD

Current Price

$7.96

Market Cap

419.3M

Sector

Health Care

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.77

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
ADCT
Founded
1999
2011
Country
United States
Switzerland
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
419.3M
484.4M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
CYRX
ADCT
Price
$7.96
$3.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
4
Target Price
$12.94
$7.75
AVG Volume (30 Days)
425.4K
750.6K
Earning Date
03-03-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
30.86
EPS
1.40
N/A
Revenue
$176,177,000.00
$81,357,000.00
Revenue This Year
$10.92
N/A
Revenue Next Year
$8.08
$68.29
P/E Ratio
$5.86
N/A
Revenue Growth
N/A
14.85
52 Week Low
$4.63
$1.05
52 Week High
$11.45
$4.98

Technical Indicators

Market Signals
Indicator
CYRX
ADCT
Relative Strength Index (RSI) 42.35 40.74
Support Level $6.57 $3.25
Resistance Level $8.52 $3.87
Average True Range (ATR) 0.39 0.27
MACD 0.05 -0.06
Stochastic Oscillator 28.43 4.63

Price Performance

Historical Comparison
CYRX
ADCT

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: